DOP2013000122A - Tableta oralmente desintegradora. - Google Patents

Tableta oralmente desintegradora.

Info

Publication number
DOP2013000122A
DOP2013000122A DO2013000122A DO2013000122A DOP2013000122A DO P2013000122 A DOP2013000122 A DO P2013000122A DO 2013000122 A DO2013000122 A DO 2013000122A DO 2013000122 A DO2013000122 A DO 2013000122A DO P2013000122 A DOP2013000122 A DO P2013000122A
Authority
DO
Dominican Republic
Prior art keywords
orally
tablet
detaching
active ingredients
proton pump
Prior art date
Application number
DO2013000122A
Other languages
English (en)
Inventor
Yasushi Mima
Tetsuya Kawano
Yumiko Ishii
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000122(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DOP2013000122A publication Critical patent/DOP2013000122A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una tableta oralmente desintegradora de una estructura de múltiples capas, la cual tiene (1) una capa que contiene microgránulos de recubrimiento entérico conteniendo un inhibidor de bomba de protones, y (2) una capa que contiene ácido acetilsalicílico. La tableta oralmente desintegradora es caracterizada porque: los ingredientes activos del mismo (el inhibidor de bomba de protones y aspirina) tienen alta estabilidad; y efectos farmacológicos de los ingredientes activos son exhibidos de manera estable y rápidamente después de la administración.
DO2013000122A 2010-12-03 2013-05-31 Tableta oralmente desintegradora. DOP2013000122A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010270276 2010-12-03

Publications (1)

Publication Number Publication Date
DOP2013000122A true DOP2013000122A (es) 2013-12-15

Family

ID=46172031

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000122A DOP2013000122A (es) 2010-12-03 2013-05-31 Tableta oralmente desintegradora.

Country Status (21)

Country Link
US (1) US20130243859A1 (es)
EP (1) EP2647381A4 (es)
JP (1) JP6037840B2 (es)
KR (1) KR101908748B1 (es)
CN (1) CN103338774A (es)
AU (1) AU2011337549A1 (es)
BR (1) BR112013013571A2 (es)
CA (1) CA2819460C (es)
CL (1) CL2013001566A1 (es)
CO (1) CO6721054A2 (es)
CR (1) CR20130287A (es)
DO (1) DOP2013000122A (es)
EA (1) EA201390814A1 (es)
EC (1) ECSP13012717A (es)
MX (1) MX2013006247A (es)
MY (1) MY180677A (es)
PE (1) PE20140005A1 (es)
SG (1) SG190717A1 (es)
TN (1) TN2013000229A1 (es)
WO (1) WO2012074110A1 (es)
ZA (1) ZA201304366B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402400YA (en) 2011-11-30 2014-06-27 Takeda Pharmaceutical Dry coated tablet
US9693962B2 (en) 2012-06-05 2017-07-04 Takeda Pharmaceutical Limited Dry-coated tablet
EP3000470A4 (en) * 2013-05-21 2017-01-11 Takeda Pharmaceutical Company Limited Orally disintegrable tablet
JP2015020964A (ja) * 2013-07-17 2015-02-02 日本曹達株式会社 ヒドロキシプロピルセルロース
CN107072997A (zh) 2014-11-11 2017-08-18 盐野义制药株式会社 含有对光不稳定的药物的多层片剂
SI3236952T1 (sl) * 2014-12-23 2019-11-29 Krka D D Novo Mesto Farmacevtski sestavek v obliki tablet
WO2016148263A1 (ja) * 2015-03-19 2016-09-22 第一三共株式会社 抗酸化剤を含有する固形製剤
WO2016148264A1 (ja) 2015-03-19 2016-09-22 第一三共株式会社 着色剤を含有する固形製剤
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP7050484B2 (ja) * 2017-12-26 2022-04-08 ライオン株式会社 積層錠、医薬製剤及び積層錠の製造方法
WO2022103233A1 (ko) * 2020-11-13 2022-05-19 (주)휴온스 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법
CN113230221B (zh) * 2021-04-06 2022-11-04 北京诚济制药股份有限公司 一种铝镁匹林片(ⅱ)
KR20230149188A (ko) 2022-04-19 2023-10-26 한미약품 주식회사 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물
KR20240043707A (ko) 2022-09-27 2024-04-03 한미약품 주식회사 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPH072761B2 (ja) 1985-03-20 1995-01-18 不二パウダル株式会社 微結晶セルロ−ス球形顆粒及びその製造法
JP2820829B2 (ja) 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
ES2179079T3 (es) * 1993-10-12 2003-01-16 Mitsubishi Pharma Corp Comprimidos que contienen granulos entericos.
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CA2407208C (en) 2000-04-28 2010-08-17 Takeda Chemical Industries, Ltd. Process for producing optically active sulfoxide derivative
ES2511774T3 (es) 2000-05-15 2014-10-23 Takeda Pharmaceutical Company Limited Formas cristalinas de (R)-lansoprazol
JP2002029964A (ja) * 2000-07-11 2002-01-29 Lion Corp 固形医薬組成物
JP2002154966A (ja) * 2000-11-22 2002-05-28 Taisho Pharmaceut Co Ltd アセチルサリチル酸アルミニウム含有組成物
HU229356B1 (en) 2000-12-01 2013-11-28 Takeda Pharmaceutical Process for the crystallization of (r)- or (s)-lansoprazole
EP2260837A1 (en) 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
JP5138856B2 (ja) * 2001-06-20 2013-02-06 武田薬品工業株式会社 錠剤の製造方法
NZ530511A (en) * 2001-07-16 2005-06-24 Astrazeneca Ab A tablet for treating disorders of the gastrointestinal tract comprising a proton pump inhibitor and at least one antacid that has a barrier layer to cover an enteric coating film
US6930099B2 (en) * 2001-09-07 2005-08-16 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
WO2005076987A2 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
EP1750767A4 (en) * 2004-05-25 2010-09-22 Santarus Inc PHARMACEUTICAL FORMULATIONS USEFUL IN INHIBITING ACID SECRETION AND METHODS OF MAKING AND USING SAME
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
CN101316596A (zh) * 2005-11-30 2008-12-03 阿斯利康(瑞典)有限公司 含有质子泵抑制剂和乙酰水杨酸作为活性成份的口服药物剂型
US8202538B2 (en) * 2006-06-26 2012-06-19 Capricorn Pharma, Inc. Orally disintegrating layered compositions
JP2009263305A (ja) * 2008-04-28 2009-11-12 Lion Corp 多層錠剤およびその製造方法
JPWO2009151116A1 (ja) * 2008-06-13 2011-11-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬

Also Published As

Publication number Publication date
KR101908748B1 (ko) 2018-10-16
JP6037840B2 (ja) 2016-12-07
CL2013001566A1 (es) 2014-05-02
CO6721054A2 (es) 2013-07-31
PE20140005A1 (es) 2014-01-23
ZA201304366B (en) 2014-02-26
AU2011337549A1 (en) 2013-07-04
TN2013000229A1 (en) 2014-11-10
US20130243859A1 (en) 2013-09-19
CR20130287A (es) 2013-10-07
KR20130124344A (ko) 2013-11-13
WO2012074110A1 (ja) 2012-06-07
EP2647381A1 (en) 2013-10-09
MY180677A (en) 2020-12-05
EP2647381A4 (en) 2015-12-23
BR112013013571A2 (pt) 2016-10-11
EA201390814A1 (ru) 2013-11-29
MX2013006247A (es) 2014-01-31
JPWO2012074110A1 (ja) 2014-05-19
CA2819460A1 (en) 2012-06-07
SG190717A1 (en) 2013-07-31
CA2819460C (en) 2017-08-01
CN103338774A (zh) 2013-10-02
ECSP13012717A (es) 2013-12-31

Similar Documents

Publication Publication Date Title
ECSP13012717A (es) Tableta oralmente desintegradora
PE20180931A1 (es) Metodo de cristalizacion y biodisponibilidad
AR089032A1 (es) Comprimido recubierto seco
NZ743714A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
ECSP088490A (es) Forma farmacéutica oral que contiene como principios activos un inhibidor de la bomba de protones junto con ácido acetilsalicílico
ECSP15039103A (es) Formulación de liberación sostenida de mosapride que proporciona efectos farmacológicos y clínicos con administración una vez al día
CO7131367A2 (es) Formulación compuesta que comprende una tableta esferoidal de múltiples unidades (must) en cápsulada en cápsula dura y método para su preparación
PE20140163A1 (es) Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
DOP2016000024A (es) Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel
PH12015502578A1 (en) Orally disintegrable tablet
CO2018000991A2 (es) Tableta
ES2623281T3 (es) Composiciones farmacéuticas sólidas con recubrimiento entérico para inhibidores de la bomba de protones.
PE20110943A1 (es) Formulacion oral solida de alisquireno
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.
PE20131064A1 (es) Preparacion de particulas recubiertas
CR20180209A (es) Formulación de liberación modificada de naproxeno sodico
TH153153A (th) ยาเม็ดเคลือบแห้ง
TH169516A (th) ยาเม็ดชนิดแตกตัวได้ในช่องปาก
UY31153A1 (es) Composicion farmaceutica combinada
TH126521A (th) สูตรทางเภสัชกรรมในรูปยาเม็ดสองชั้นที่ประกอบรวมด้วย hmg-coaรีดัคเทส อินฮิบิเตอร์ และเออร์เบซาร์แทน
TR201005328A2 (tr) Kolesevelam içeren çok tabakalı tablet dozaj formu@
TH134258A (th) ยาเม็ดชนิดแตกตัวในปาก
AR078107A1 (es) Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
IN2013MU03390A (es)
UA111358C2 (uk) Тверда лікарська форма препарату седативної та снодійної дії